Pharmacologic activation of PPARγ inhibited dermal fibrogenesis by suppressing the early growth response protein 1, a mediator of non-Smad TGF-β1 signaling [24], and maintained normal epithelial phenotype, prevented renal fibrosis and oxidative stress in mice [67]. This evidence concerns the gene PPARG and renal fibrosis.